Pharm-Olam International - A Contract Research Organization

Urinary Retention (Rescue)

Pharm-Olam was asked to assist with recruitment in this trial (managed by another CRO) as enrollment was slower than predicted. Initially, the sponsor's request was for 100 patients over a period of 5 months. Pharm-Olam quickly set up 8 sites in Eastern Europe and achieved the target a few weeks ahead of schedule.

Impressed by our performance, the sponsor extended their patient target 4 times to Pharm-Olam during the study. In the end, Pharm-Olam recruited 477 patients and stayed ahead of the target throughout the study's duration.

The sponsor made the right choice selecting Pharm-Olam for accelerated recruitment, because their drug later received NDA approval — giving them a time advantage over their competitors.

Urology Studies

Benign Prostatic Hyperplasia
Dysfunctional Voiding
Hydronephrosis
Nocturia
Overactive Bladder
Premature Ejaculation
Renal Impairment
Urinary Incontinence
Urinary Retention

Argentina (Buenos Aires), Belarus (Minsk), Belgium (Brussels), Brazil (São Paulo), Bulgaria (Sofia), Canada (Toronto), Croatia (Zagreb), Czech Rep. (Prague), Georgia (Tbilisi), Germany (Munich), Hungary (Budapest), India (Bangalore), Italy (Milan), Kazakhstan (Almaty), Mexico (Mexico City), Poland (Warsaw), Romania (Bucharest), Russia (Moscow, St. Petersburg, Novosibirsk), Serbia (Belgrade), Spain (Madrid), South Africa (Johannesburg), Ukraine (Kiev), United Kingdom (London), United States (Houston, Princeton, Research Triangle Park)